Bridgebio Pharma Stock Price Prediction
| BBIO Stock | USD 77.87 0.06 0.08% |
Momentum 57
Buy Extended
Oversold | Overbought |
EPS Estimate Next Quarter (0.66) | EPS Estimate Current Year (3.19) | EPS Estimate Next Year (1.77) | Wall Street Target Price 89.7895 | EPS Estimate Current Quarter (0.78) |
Using BridgeBio Pharma hype-based prediction, you can estimate the value of BridgeBio Pharma from the perspective of BridgeBio Pharma response to recently generated media hype and the effects of current headlines on its competitors. We also analyze overall investor sentiment towards BridgeBio Pharma using BridgeBio Pharma's stock options and short interest. It helps to benchmark the overall future attitude of investors towards BridgeBio using crowd psychology based on the activity and movement of BridgeBio Pharma's stock price.
BridgeBio Pharma Short Interest
An investor who is long BridgeBio Pharma may also wish to track short interest. As short interest increases, investors should be becoming more worried about BridgeBio Pharma and may potentially protect profits, hedge BridgeBio Pharma with its derivative instruments, or be ready for some potential downside.
200 Day MA 52.8212 | Short Percent 0.1491 | Short Ratio 9.63 | Shares Short Prior Month 18.8 M | 50 Day MA 73.4502 |
BridgeBio Pharma Hype to Price Pattern
Investor biases related to BridgeBio Pharma's public news can be used to forecast risks associated with an investment in BridgeBio. The trend in average sentiment can be used to explain how an investor holding BridgeBio can time the market purely based on public headlines and social activities around BridgeBio Pharma. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Some investors profit by finding stocks that are overvalued or undervalued based on market sentiment. The correlation of BridgeBio Pharma's market sentiment to its price can help taders to make decisions based on the overall investors consensus about BridgeBio Pharma.
BridgeBio Pharma Implied Volatility | 0.66 |
BridgeBio Pharma's implied volatility exposes the market's sentiment of BridgeBio Pharma stock's possible movements over time. However, it does not forecast the overall direction of its price. In a nutshell, if BridgeBio Pharma's implied volatility is high, the market thinks the stock has potential for high price swings in either direction. On the other hand, the low implied volatility suggests that BridgeBio Pharma stock will not fluctuate a lot when BridgeBio Pharma's options are near their expiration.
The fear of missing out, i.e., FOMO, can cause potential investors in BridgeBio Pharma to buy its stock at a price that has no basis in reality. In that case, they are not buying BridgeBio because the equity is a good investment, but because they need to do something to avoid the feeling of missing out. On the other hand, investors will often sell stocks at prices well below their value during bear markets because they need to stop feeling the pain of losing money.
BridgeBio Pharma after-hype prediction price | USD 78.59 |
There is no one specific way to measure market sentiment using hype analysis or a similar predictive technique. This prediction method should be used in combination with more fundamental and traditional techniques such as stock price forecasting, technical analysis, analysts consensus, earnings estimates, and various momentum models.
Prediction based on Rule 16 of the current BridgeBio contract
Based on the Rule 16, the options market is currently suggesting that BridgeBio Pharma will have an average daily up or down price movement of about 0.0413% per day over the life of the 2026-04-17 option contract. With BridgeBio Pharma trading at USD 77.87, that is roughly USD 0.0321 . If you think that the market is fully incorporating BridgeBio Pharma's daily price movement you should consider acquiring BridgeBio Pharma options at the current volatility level of 0.66%. But if you have an opposite viewpoint you should avoid it and even consider selling them.
BridgeBio | Build AI portfolio with BridgeBio Stock |
BridgeBio Pharma After-Hype Price Density Analysis
As far as predicting the price of BridgeBio Pharma at your current risk attitude, this probability distribution graph shows the chance that the prediction will fall between or within a specific range. We use this chart to confirm that your returns on investing in BridgeBio Pharma or, for that matter, your successful expectations of its future price, cannot be replicated consistently. Please note, a large amount of money has been lost over the years by many investors who confused the symmetrical distributions of Stock prices, such as prices of BridgeBio Pharma, with the unreliable approximations that try to describe financial returns.
Next price density |
| Expected price to next headline |
BridgeBio Pharma Estimiated After-Hype Price Volatility
In the context of predicting BridgeBio Pharma's stock value on the day after the next significant headline, we show statistically significant boundaries of downside and upside scenarios based on BridgeBio Pharma's historical news coverage. BridgeBio Pharma's after-hype downside and upside margins for the prediction period are 76.40 and 80.78, respectively. We have considered BridgeBio Pharma's daily market price in relation to the headlines to evaluate this method's predictive performance. Remember, however, there is no scientific proof or empirical evidence that news-based prediction models outperform traditional linear, nonlinear models or artificial intelligence models to provide accurate predictions consistently.
Current Value
BridgeBio Pharma is very steady at this time. Analysis and calculation of next after-hype price of BridgeBio Pharma is based on 3 months time horizon.
BridgeBio Pharma Stock Price Outlook Analysis
Have you ever been surprised when a price of a Company such as BridgeBio Pharma is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading BridgeBio Pharma backward and forwards among themselves. Have you ever observed a lot of a particular company's price movement is driven by press releases or news about the company that has nothing to do with actual earnings? Usually, hype to individual companies acts as price momentum. If not enough favorable publicity is forthcoming, the Stock price eventually runs out of speed. So, the rule of thumb here is that as long as this news hype has nothing to do with immediate earnings, you should pay more attention to it. If you see this tendency with BridgeBio Pharma, there might be something going there, and it might present an excellent short sale opportunity.
| Expected Return | Period Volatility | Hype Elasticity | Related Elasticity | News Density | Related Density | Expected Hype |
0.28 | 2.19 | 1.36 | 0.32 | 15 Events / Month | 8 Events / Month | In about 15 days |
| Latest traded price | Expected after-news price | Potential return on next major news | Average after-hype volatility | |
77.87 | 78.59 | 1.00 |
|
BridgeBio Pharma Hype Timeline
BridgeBio Pharma is currently traded for 77.87. The entity has historical hype elasticity of -1.36, and average elasticity to hype of competition of 0.32. BridgeBio is forecasted to increase in value after the next headline, with the price projected to jump to 78.59 or above. The average volatility of media hype impact on the company the price is about 44.97%. The price boost on the next news is projected to be 1.0%, whereas the daily expected return is currently at 0.28%. The volatility of related hype on BridgeBio Pharma is about 192.11%, with the expected price after the next announcement by competition of 78.19. The company reported the previous year's revenue of 221.9 M. Net Loss for the year was (543.35 M) with profit before overhead, payroll, taxes, and interest of 338.84 M. Given the investment horizon of 90 days the next forecasted press release will be in about 15 days. Check out BridgeBio Pharma Basic Forecasting Models to cross-verify your projections.BridgeBio Pharma Related Hype Analysis
Having access to credible news sources related to BridgeBio Pharma's direct competition is more important than ever and may enhance your ability to predict BridgeBio Pharma's future price movements. Getting to know how BridgeBio Pharma's peers react to changing market sentiment, related social signals, and mainstream news is a great way to find investing opportunities and time the market. The summary table below summarizes the essential lagging indicators that can help you analyze how BridgeBio Pharma may potentially react to the hype associated with one of its peers.
| HypeElasticity | NewsDensity | SemiDeviation | InformationRatio | PotentialUpside | ValueAt Risk | MaximumDrawdown | |||
| RVMD | Revolution Medicines | 12.18 | 9 per month | 2.90 | 0.20 | 5.23 | (2.52) | 32.00 | |
| IONS | Ionis Pharmaceuticals | 1.16 | 8 per month | 1.62 | 0.06 | 3.19 | (2.67) | 8.64 | |
| ASND | Ascendis Pharma AS | (5.25) | 12 per month | 2.06 | 0.07 | 4.74 | (4.28) | 11.01 | |
| SMMT | Summit Therapeutics PLC | 1.20 | 11 per month | 0.00 | (0.06) | 5.41 | (5.75) | 23.61 | |
| ROIV | Roivant Sciences | 0.07 | 10 per month | 1.44 | 0.15 | 4.37 | (2.84) | 9.44 | |
| MRNA | Moderna | 1.87 | 7 per month | 3.69 | 0.17 | 10.85 | (7.01) | 23.11 | |
| BMRN | Biomarin Pharmaceutical | (1.16) | 9 per month | 1.68 | 0.02 | 3.20 | (3.05) | 22.06 | |
| EXEL | Exelixis | 1.47 | 11 per month | 1.61 | 0.10 | 4.27 | (2.93) | 11.45 | |
| RNA | Avidity Biosciences | 0.04 | 13 per month | 0.00 | 0.12 | 1.23 | (0.40) | 42.94 | |
| JAZZ | Jazz Pharmaceuticals PLC | (0.18) | 8 per month | 1.68 | 0.08 | 3.66 | (3.14) | 25.96 |
BridgeBio Pharma Additional Predictive Modules
Most predictive techniques to examine BridgeBio price help traders to determine how to time the market. We provide a combination of tools to recognize potential entry and exit points for BridgeBio using various technical indicators. When you analyze BridgeBio charts, please remember that the event formation may indicate an entry point for a short seller, and look at other indicators across different periods to confirm that a breakdown or reversion is likely to occur.| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
About BridgeBio Pharma Predictive Indicators
The successful prediction of BridgeBio Pharma stock price could yield a significant profit to investors. But is it possible? The efficient-market hypothesis suggests that all published stock prices of traded companies, such as BridgeBio Pharma, already reflect all publicly available information. This academic statement is a fundamental principle of many financial and investing theories used today. However, the typical investor usually disagrees with a 'textbook' version of this hypothesis and continually tries to find mispriced stocks to increase returns. We use internally-developed statistical techniques to arrive at the intrinsic value of BridgeBio Pharma based on analysis of BridgeBio Pharma hews, social hype, general headline patterns, and widely used predictive technical indicators.
We also calculate exposure to BridgeBio Pharma's market risk, different technical and fundamental indicators, relevant financial multiples and ratios, and then comparing them to BridgeBio Pharma's related companies. | 2025 | 2026 (projected) | Dividend Yield | 3.11E-4 | 3.98E-4 | Price To Sales Ratio | 26.46 | 25.14 |
Pair Trading with BridgeBio Pharma
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if BridgeBio Pharma position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in BridgeBio Pharma will appreciate offsetting losses from the drop in the long position's value.Moving together with BridgeBio Stock
Moving against BridgeBio Stock
| 0.84 | DRMA | Dermata Therapeutics | PairCorr |
| 0.76 | VINC | Vincerx Pharma Common | PairCorr |
| 0.73 | AMRN | Amarin PLC | PairCorr |
| 0.71 | SLN | Silence Therapeutics PLC Downward Rally | PairCorr |
| 0.66 | VYGR | Voyager Therapeutics | PairCorr |
| 0.66 | REVB | Revelation Biosciences | PairCorr |
The ability to find closely correlated positions to BridgeBio Pharma could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace BridgeBio Pharma when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back BridgeBio Pharma - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling BridgeBio Pharma to buy it.
The correlation of BridgeBio Pharma is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as BridgeBio Pharma moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if BridgeBio Pharma moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for BridgeBio Pharma can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out BridgeBio Pharma Basic Forecasting Models to cross-verify your projections. To learn how to invest in BridgeBio Stock, please use our How to Invest in BridgeBio Pharma guide.You can also try the Stocks Directory module to find actively traded stocks across global markets.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of BridgeBio Pharma. If investors know BridgeBio will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about BridgeBio Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (4.21) | Revenue Per Share | Quarterly Revenue Growth 43.18 | Return On Assets | Return On Equity |
The market value of BridgeBio Pharma is measured differently than its book value, which is the value of BridgeBio that is recorded on the company's balance sheet. Investors also form their own opinion of BridgeBio Pharma's value that differs from its market value or its book value, called intrinsic value, which is BridgeBio Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because BridgeBio Pharma's market value can be influenced by many factors that don't directly affect BridgeBio Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between BridgeBio Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if BridgeBio Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, BridgeBio Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.